Double-disk synergy test positivity in Stenotrophomonas maltophilia clinical strains
Jazyk angličtina Země Spojené státy americké Médium print
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
15114869
DOI
10.1007/bf02931649
Knihovny.cz E-zdroje
- MeSH
- ampicilin farmakologie MeSH
- antibakteriální látky farmakologie MeSH
- bakteriální léková rezistence MeSH
- beta-laktamy farmakologie MeSH
- inhibitory beta-laktamasy * MeSH
- inhibitory enzymů farmakologie MeSH
- kombinace amoxicilinu a kyseliny klavulanové farmakologie MeSH
- kombinace léků piperacilin a tazobactam MeSH
- kyselina penicilanová analogy a deriváty farmakologie MeSH
- mikrobiální testy citlivosti metody MeSH
- piperacilin farmakologie MeSH
- Stenotrophomonas maltophilia růst a vývoj izolace a purifikace metabolismus MeSH
- sulbaktam farmakologie MeSH
- synergismus léků MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- ampicilin MeSH
- antibakteriální látky MeSH
- beta-laktamy MeSH
- inhibitory beta-laktamasy * MeSH
- inhibitory enzymů MeSH
- kombinace amoxicilinu a kyseliny klavulanové MeSH
- kombinace léků piperacilin a tazobactam MeSH
- kyselina penicilanová MeSH
- piperacilin MeSH
- sulbaktam MeSH
- sultamicillin MeSH Prohlížeč
The double-disk synergy test (DDST) using Mueller-Hinton agar and antibiotic disks with centrally positioned disks of amoxicillin-clavulanate, ampicillin-sulbactam, and piperacillin-tazobactam and, at a center-to-center distance of 25-30 mm, 2-4 disks with 10 various beta-lactam antibiotics per one plate was performed in 58 clinical isolates of Stenotrophomonas maltophilia to determine the effectivity of 3 beta-lactamase inhibitors. When tested with clavulanate as the central beta-lactamase inhibitor synergic action on tested strains was the most frequent with aztreonam (81.0% of strains), cefoperazone (63.8%), and cefepime (60.3%). With sulbactam the synergic action, i.e. DDST positivity, was high in the case of cefoperazone (15.5%), ampicillin, aztreonam and piperacillin (8.6% each); with tazobactam it was the most frequent with aztreonam (53.4%), cefoperazone (44.8%) and cefepime (37.9%). No synergy was demonstrated after application of meropenem regardless of the kind of beta-lactamase inhibitor used. In 58 strains of S. maltophilia, 55 different profiles of DDST positivity were found. The results confirm that clavulanate is the most effective inhibitor of S. maltophilia beta-lactamases. The utilization of DDST (performed in the recommended way) for the typization of strains Stenotrophomonas species and for the estimation of potential effectiveness combinations of beta-lactams with beta-lactamase inhibitors for the therapy of stenotrophomonade infections was suggested.
Zobrazit více v PubMed
Folia Microbiol (Praha). 2002;47(6):742-6 PubMed
Rev Infect Dis. 1988 Jul-Aug;10(4):867-78 PubMed
Antimicrob Agents Chemother. 1994 Sep;38(9):2143-9 PubMed
Antimicrob Agents Chemother. 1994 May;38(5):991-6 PubMed
J Hosp Infect. 1991 Aug;18(4):324-5 PubMed
Infection. 1998 May-Jun;26(3):187-8 PubMed
Antimicrob Agents Chemother. 1982 Oct;22(4):564-70 PubMed
Int J Syst Evol Microbiol. 2000 Jan;50 Pt 1:273-82 PubMed
J Antimicrob Chemother. 1996 Feb;37(2):394-6 PubMed
Antimicrob Agents Chemother. 1995 Jan;39(1):192-9 PubMed
J Antimicrob Chemother. 1998 Apr;41(4):493-4 PubMed
Antimicrob Agents Chemother. 2001 May;45(5):1581-4 PubMed
Antimicrob Agents Chemother. 1994 Oct;38(10):2317-22 PubMed
Diagn Microbiol Infect Dis. 1997 Nov;29(3):129-32 PubMed
Clin Microbiol Rev. 1998 Jan;11(1):57-80 PubMed
Antimicrob Agents Chemother. 1984 Mar;25(3):362-5 PubMed
